ArticleJournal for immunotherapy of cancer2021

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.

Kevin Conlon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.